OBJECTIVE: Metastatic bone disease (MBD) and subsequent skeletal-related events (SREs) are common complications secondary to solid tumors. We conducted a retrospective analysis of US health insurance claims to examine the cost of SREs among patients with MBD secondary to breast, lung, or prostate cancer. METHODS: Data were obtained from i3's Lab Rx Database from May 1, 2000 to March 31, 2005. Patients were included if they had at least two ICD-9 diagnoses of breast, lung, or prostate cancer; at least two diagnoses of MBD; and at least one SRE on or after the initial MBD diagnosis. SREs were defined as a pathological fracture, spinal cord compression, surgery to the bone, or radiation to the bone and were identified using ICD-9 and CPT-4 codes. Patients had to be continuously insured for at least six months prior to their first SRE (index date) and one month after their index date. Descriptive statistics were calculated and the annual cost of SREs was estimated using Kaplan-Meier curves to adjust for censoring. RESULTS: In the study period, 3584 patients were diagnosed with breast, lung, or prostate cancer and MBD, and 1840 (51%) experienced at least one incident SRE. Regardless of tumor type, patients were most frequently found to have radiation therapy (86%-89%) followed by pathological fracture (23%-29%), bone surgery (12%-16%), and spinal cord compression (7%-9%). The adjusted mean costs associated with SREs in the one year after the index SRE ranged from $12,469 to $17,408, with the highest costs associated with radiation therapy ($5930 to $7152), pathological fracture ($3179 to $6624), and bone surgery ($2218 to $2536). CONCLUSION: This analysis of patients with cancer-related MBD revealed that the incidence of SREs is high and their annual economic impact is substantial regardless of tumor type. Patients were included if they had at least 2 ICD-9 diagnoses of MM (ICD-9 203.0x); and at least 1 SRE on or after the initial MM diagnosis. SREs were defined as a pathological fracture, spinal cord compression, surgery to the bone, or radiation to the bone and were identified using ICD-9 and CPT-4 codes. Patients had be continuously insured for at least six months prior to their first SRE (index date) and one month after their index date. Descriptive statistics were calculated and annual cost of SREs was estimated using KaplanMeier curves to adjust for censoring. RESULTS: In the study period, 876 patients were diagnosed with MM, and 429 (49%) experienced at least 1 incident SRE. The mean time from MM diagnosis to index SRE was 259 days. Pathological fracture (60%) and radiation therapy (59%) were the most frequently experienced SREs followed by surgery to the bone (23%). Among these patients, 61% had 1 type of SRE, 27% had 2 types of SREs and 12% had 3 or more. The mean charges associated with SREs in the 1 year post SRE was $20,285, with the highest charges associated with pathological fracture ($11,370), followed by bone surgery ($4,020), and radiation therapy ($2,966). CONCLUSION: This analysis of patients with MM revealed that the incidence of SREs is high and their annual economic impact is substantial.
Patients were included if they had at least two ICD-9 diagnoses of breast, lung, or prostate cancer; at least two diagnoses of MBD; and at least one SRE on or after the initial MBD diagnosis. SREs were defined as a pathological fracture, spinal cord compression, surgery to the bone, or radiation to the bone and were identified using ICD-9 and CPT-4 codes. Patients had to be continuously insured for at least six months prior to their first SRE (index date) and one month after their index date. Descriptive statistics were calculated and the annual cost of SREs was estimated using Kaplan-Meier curves to adjust for censoring. RESULTS: In the study period, 3584 patients were diagnosed with breast, lung, or prostate cancer and MBD, and 1840 (51%) experienced at least one incident SRE. Regardless of tumor type, patients were most frequently found to have radiation therapy (86%-89%) followed by pathological fracture (23%-29%), bone surgery (12%-16%), and spinal cord compression (7%-9%). The adjusted mean costs associated with SREs in the one year after the index SRE ranged from $12,469 to $17,408, with the highest costs associated with radiation therapy ($5930 to $7152), pathological fracture ($3179 to $6624), and bone surgery ($2218 to $2536) . CONCLUSION: This analysis of patients with cancer-related MBD revealed that the incidence of SREs is high and their annual economic impact is substantial regardless of tumor type. Patients were included if they had at least 2 ICD-9 diagnoses of MM (ICD-9 203.0x); and at least 1 SRE on or after the initial MM diagnosis. SREs were defined as a pathological fracture, spinal cord compression, surgery to the bone, or radiation to the bone and were identified using ICD-9 and CPT-4 codes. Patients had be continuously insured for at least six months prior to their first SRE (index date) and one month after their index date. Descriptive statistics were calculated and annual cost of SREs was estimated using KaplanMeier curves to adjust for censoring. RESULTS: In the study period, 876 patients were diagnosed with MM, and 429 (49%) experienced at least 1 incident SRE. The mean time from MM diagnosis to index SRE was 259 days. Pathological fracture (60%) and radiation therapy (59%) were the most frequently experienced SREs followed by surgery to the bone (23%). Among these patients, 61% had 1 type of SRE, 27% had 2 types of SREs and 12% had 3 or more. The mean charges associated with SREs in the 1 year post SRE was $20,285, with the highest charges associated with pathological fracture ($11,370), followed by bone surgery ($4,020), and radiation therapy ($2,966) . CONCLUSION: This analysis of patients with MM revealed that the incidence of SREs is high and their annual economic impact is substantial. (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) Medicare claims. Subjects aged Ն65 years with Ն1 stage IIB or higher melanoma diagnosis were selected. Index dates was defined as the date of the first observed stage IIB or higher diagnosis. Utilization and costs were descriptively analyzed for each patient from their index date until death, interruption of benefits coverage (Ն6 months), or end of the database (December 31, 2005) . RESULTS: A total of 6470 subjects met all inclusion criteria. Stage distribution was: IIB/C (38%); IIIA/B (46%); IIIC (1%); IV (15%). Median follow-up was 56, 39, 16, and 6 months for each stage, respectively. On average, patients with stage IV disease incurred 3.1 hospital days per month, compared to 0.5, 0.6, and 1.1 days per month for subjects with stage IIB/C, IIIA/B, and IIIC melanoma, respectively (all P < 0.001). Mean inpatient costs for stage IV disease were $3337 per patient per month, versus $589, $880, and $1465 for stages IIB/C, IIIA/B, and IIIC, respectively (all P < 0.001). Total health care costs, excluding prescription drugs, were $8190 per patient per month for stage IV disease, compared to $1703, $2536, $4880 for stages IIB/C, IIIA/B, and IIIC, respectively (all P < 0.001). CONCLUSION: This study provides stage-specific estimates of resource utilization and costs in high risk and metastatic melanoma using real-world administrative data. Findings Abstracts A69
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